Shenzhen Immunofoco (2633140D HK): Synthetic Expert Call Transcript (21 Aug 2026)
The commercial viability of in vivo CAR-T platforms like Immunofoco’s iMAGIC hinges on the biological trade-offs of using a viral vector. While...
92 Views
IPO Databook: Shenzhen Immunofoco Biotechnology (HK) - Aug 2026
Shenzhen Immunofoco Biotechnology, founded in 2020, is an innovative cell therapy company developing CAR-T therapies for solid tumors,...
118 Views
Shenzhen Immunofoco (易慕峰) Pre-IPO: Structural Challenge for Monetization
China's Shenzhen Immunofoco seeks to raise $100 million through Hong Kong listing with Huatai as sole sponsor. We look at its late-stage product...
211 Views
Aequitas ECM Weekly (16 March 2026)- Past A/H Trends, Delton, Raajmarg, Ringpai, FS.com, Everdisplay
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
303 Views
No more insights